Moderna found that its coronavirus vaccine was 96% effective in adolescents aged 12-17 based on early results from late-stage clinical trials. The announcement comes as several companies begin to seek regulatory approval to administer their vaccines in children and adolescents (including Pfizer, which announced plans to seek authorization for children aged 2-11 by September).
The New Paper
This story is from the May 7, 2021 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.
